ArticleCellular oncology (Dordrecht, Netherlands)2025
Elimination of docetaxel-induced senescence attenuates malignant progression in RB1-deficient CRPC.
Article in Cellular oncology (Dordrecht, Netherlands), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purpose retinoblastoma l(RB1) mutations frequently emerge as late subclonal events in advanced prostate cancer (PCa), driving inevitable recurrence and therapy resistance. Therapy-induced senescence (TIS) could promote metastasis at a late stage. However, the underlying mechanisms and therapeutic approaches for decetaxel-induced senescence (DIS) in RB1-deficient castration-resistant prostate cancer (CRPC) remain poorly understood.
methodsWe systematically evaluated the association between RB1 expression and tumor malignancy using TCGA-PRAD data and clinical prostate cancer samples. Multiple CRPC models were established, including RM-1 C57BL/6 and PC-3 BALB/c-nu mouse models, as well as human PC-3 and 22RV1 cells to uncover the double-edged nature of DIS. Subsequently, RNA sequencing of shRB1-DIS identified tumorigenic SASP factors. Furthermore, we investigated the molecular mechanisms of the combined treatment using techniques such as immunofluorescence, flow cytometry, chromatin immunoprecipitation (ChIP), dual luciferase reporter assay, and molecular docking.
resultsThe clinical significance and negative correlation between RB1 expression and malignancy were verified in human PCa samples. Using murine and human CRPC models, we demonstrated that DIS response was retained in both RB1-knockdown and control groups. Strikingly, DIS promoted metastasis and accelerated the transition to neuroendocrine prostate cancer (NEPC) in RB1-deficient models. shRB1-DIS was marked by elevated senescence-associated β-galactosidase (SA-β-gal) activity and upregulation of p27
conclusionDIS accelerates the malignant progression of shRB1 CRPC, mediated by tumorigenic SASP, especially IL-20 enrichment. Notably, we identifies a novel FOXA1-IL-20-IL20Rβ axis that drives M2-like macrophage polarization and contributes to tumor aggressiveness and docetaxel resistance. Importantly, senolytic agent ABT-263 not only selectively eliminated shRB1-DIS cells but also restricted expression of tumorigenic SASPs, thereby restoring sensitivity to docetaxel. Wherein, IL-20 is inhibited through its interaction with ABT-263. These results provide a novel mechanistic rationale for using senolytic therapies to mitigate SASP-driven malignancy and improve treatment response in RB1-deficient CRPC. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.